The US cancer pain management market is projected to grow from $2.74 Bn in 2022 to $3.55 Bn by 2030, registering a CAGR of 3.33% during the forecast period of 2022-30. The main factors driving the growth would be increasing cancer incidence, the launch of new and advanced pain management drugs, government initiatives, and the growing need for non-invasive and minimally invasive pain management methods. The market is segmented by drug type and by disease. Some of the major players include Collegium Pharmaceutical (USA), Pfizer (USA), Abbott (USA), Sorrento Therapeutics (USA), Galena Biopharma (USA), Hisamitsu Pharmaceutical, Aoxing Pharmaceutical, Orexo, and Teva Pharmaceuticals.
The US cancer pain management market is projected to grow from $2.74 Bn in 2022 to $3.55 Bn by 2030, registering a CAGR of 3.33% during the forecast period of 2022-30. US national healthcare spending as a share of GDP in 2021 was 18.3% or $12,914 per person. In terms of both public and private healthcare spending, the US spends the most on healthcare compared to GDP among all developed nations.
Cancer pain may be caused by the actual condition of the disease or by treatments like chemotherapy and surgery that are linked to it. The selection of drugs and their use is influenced by the kind, location, and intensity of pain felt. For the treatment of cancer pain, many different medications are employed. For instance, strong opioids are chosen when treating severe pain, but acetaminophen and NSAIDs, which are non-opioids, are preferred for treating mild to moderate cancer pain. North America accounts for a major share of the global cancer pain management market and the US is the largest market for cancer pain management in North America.
Market Growth Drivers
The US cancer pain management market is expected to be driven by factors such as increasing cancer incidence, the launch of new and advanced pain management drugs, and the growing need for non-invasive and minimally invasive pain management methods. Moreover, the US government has started a number of initiatives to improve cancer care, including funding novel cancer treatments and cancer research. These activities are anticipated to fuel the expansion of the US market for cancer pain management.
Market Restraints
Some pain management drugs have adverse effects such as nausea, vertigo, urine retention, sleep problems, and constipation, which can limit their use and have an effect on the expansion of the cancer pain management market. Further, the US Food and Drug Administration (FDA) maintains stringent guidelines for new drug approval, which can delay the research and introduction of new cancer pain management treatments.
Key Players
March 2022: Collegium Pharmaceutical acquired BioDelivery Sciences International (BDSI) to create a leading, diversified specialty pharmaceutical firm dedicated to enhancing the lives of patients with significant medical conditions. The acquisition was set up as a cash tender offer to buy all of the outstanding shares of BDSI for $5.60 each.
June 2021: Sorrento Therapeutics acquired ACEA Therapeutics. With this acquisition, other NCE therapeutic product candidates will be added, including the previously licensed anchoring small molecule medication Abivertinib, which is used to treat a variety of cancers and autoimmune diseases.
The US Food and Drug Administration is largely in charge of regulating the healthcare system and the regulatory environment for the US pain management sector (FDA). Both prescription and over-the-counter (OTC) pain management medications are subject to FDA regulation regarding their development, approval, and marketing in the US. For medications used to treat pain, the FDA establishes guidelines for their quality, safety, and efficacy. The Controlled Substances Act (CSA) divides pain management drugs into schedules according to their potential for misuse and recognized medicinal uses, with Schedule I substances having the highest potential for abuse and no accepted medical uses. The availability, prescription, and distribution of medications for pain management are impacted by this classification.
To address the opioid epidemic, the Comprehensive Addiction and Recovery Act (CARA) aims to improve Prescription Drug Monitoring Programs (PDMPs) and expand access to overdose prevention and addiction treatment services. This has an effect on the availability and prescription of opioid-based medications.
The reimbursement scenario for the pain management market in the US is influenced by factors such as the type of pain management treatment, the payer, and the patient's insurance coverage. Medicare- a government health insurance program for seniors 65 and older and Medicaid-a joint federal-state program for low-income individuals, provides coverage for a variety of pain management therapies including prescription medications, medical procedures, and hospital care. Private insurance companies frequently reimburse for a variety of pain management therapies, such as prescription medications, surgical procedures, and physical therapy but the individual's plan determines the precise coverage. Some pain management procedures might not be reimbursed by insurance, and patients might have to pay out of pocket. This can include some procedures as well as complementary therapies like acupuncture and chiropractic treatment.
1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Type (Revenue, USD Billion):
Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.
By Disease Indication (Revenue, USD Billion):
Based on disease Indication the market is segmented into:
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.